Home / Knowledge Centre /
Case study

Preparing “Plan B” for a mega study in the event of a supply issue

What do you do when a “what if” scenario becomes a distinct possibility and has the potential to interrupt your mega-study involving over 10,000 patients in hundreds of sites in various countries around the globe. How do you minimise the risk of treatment interruption, unintentional unblinding and drug wastage if you must switch modes of drug administration mid-study? For one leading pharmaceutical company, the answer was to rely on Almac Clinical Technologies, solutions to provide a contingency plan that could be activated at any moment.

View Resource
Almac Logo

Almac Clinical Technologies

Almac Clinical Technologies is here to help the biopharmaceutical industry bring new therapies to those in need by empowering clinical trial sponsors to proactively manage sites, patients, and clinical trial supplies through our industry-leading Interactive Response Technology (IRT) and expert consultancy.

Almac Clinical Technologies is uniquely positioned to unlock new efficiencies in the clinical supply chain and to help achieve greater predictability in your projects and programs.

Our professionals are dedicated to delivering high-quality Interactive Response Technology (IRT) solutions, dependable professional services, and reliable customer service. Our expertise, energy, and commitment have earned us a reputation as a trusted ally in the drug development process.

Learn More

Download here instantly

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies